Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 2

Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy

NCT02710253 · View on ClinicalTrials.gov ↗

Study Summary

This phase II trial studies the side effects and best dose of radiation therapy and to see how well it works in treating patients with cancer that has spread to other places in the body (metastatic) or has increased in size after being treated with immunotherapy. Giving radiation therapy may help to control the cancer after the disease has gotten worse after receiving immunotherapy in patients with cancer that has spread to the other places in the body.

Interventions

  • RADIATION External Beam Radiation Therapy
  • RADIATION Stereotactic Body Radiation Therapy
  • OTHER Laboratory Biomarker Analysis

Study Locations (5)

Texas

  • MD Anderson in The Woodlands — Conroe
  • M D Anderson Cancer Center — Houston
  • MD Anderson West Houston — Houston
  • MD Anderson League City — League City
  • MD Anderson in Sugar Land — Sugar Land

Trial Details

FieldValue
Enrollment Target 230 participants
Start Date 2016-05-25
Est. Completion 2026-05-30
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,992 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02710253

The ClinicalTrials.gov registry entry for NCT02710253 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,992 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Hematopoietic and Lymphoid Cell Neoplasm appearing as the primary indexed condition, and to 3 interventions — of which External Beam Radiation Therapy is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02710253 reports 5 study locations spanning 1 distinct geographic area — top geographies include Texas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02710253 about?

NCT02710253 is a clinical study titled "Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy". This phase II trial studies the side effects and best dose of radiation therapy and to see how well it works in treating patients with cancer that has spread to other places in the body (metastatic) or has increased in size after being treated with immunotherapy. Giving radiation therapy may help to...

What is the current status of trial NCT02710253?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 230 participants. The study started on 2016-05-25. Estimated completion is 2026-05-30.

What conditions does trial NCT02710253 study?

This clinical trial studies the following conditions: Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Neoplasm. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT02710253?

The interventions under investigation include: External Beam Radiation Therapy (RADIATION), Stereotactic Body Radiation Therapy (RADIATION), Laboratory Biomarker Analysis (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT02710253?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,992 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02710253 being conducted?

This trial has 5 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial